LIXT: Lixte Biotechnology Holdings Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
Stocks in this Quantisnow insightHealth Care
Historical context for LIXT
Across the 10 sessions after earlier LIXT headlines, the stock closed higher 5 times and lower 5 times, with a median move of 2.7% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | LIXT | SPY |
|---|---|---|---|
| Feb 18, 2026 | LIXTE Biotechnology Appoints Sidney Braun as CEO of its Liora Technologies Europe Ltd. Subsidiary | +1.3% | +0.5% |
| Jan 21, 2026 | DE LA SOUL-LED "GOOD HEALTH SUMMIT" LAUNCHES FEBRUARY 19 AT MOREHOUSE COLLEGE | +3.9% | +1.2% |
| Jan 20, 2026 | LIXTE Biotechnology Attending the DealFlow Discovery Conference, January 28-29 | -8.4% | -2.0% |
| Jan 13, 2026 | IBN Initiates Coverage of LIXTE Biotechnology Holdings Inc. | -1.8% | -0.2% |
| Dec 23, 2025 | LIXTE and its Collaborators Expand Clear Cell Ovarian Cancer Trialand 1 other headline that session | -1.9% | +0.5% |
| Dec 18, 2025 | Lixte Biotechnology Holdings, Inc. Announces $4.3 Million Registered Direct Offering Priced at the Market Under Nasdaq Rules | -1.0% | +0.8% |
Quantisnow market dataNASDAQ
LIXT
Lixte Biotechnology Holdings Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
Get push alerts for LIXT
Full LIXT profile on Quantisnow Follow LIXT and get a push notification the moment its next story breaks.
Original source Picked up and delivered by Quantisnow in real time